摘要
为了探讨不同年龄急性心肌梗塞患者静脉溶栓治疗的有效性及安全性，本试验对１１３例起病在２４ｈ内的患者行尿激酶静脉溶栓治疗，剂量１００～１５０万Ｕ加生理盐水１００ｍｌ３０ｍｉｎ内静滴。分＜４９岁，５０～５９岁，６０～６９岁，≥７０岁４个年龄组进行分析比较。结果各年龄组６ｈ内再通率，出血等并发症及５周病死率无显著性差异（Ｐ＞０．５）；７～１２ｈ再通率前３组无显著差异（Ｐ＞０．５），≥７０岁组无再通；＞１２ｈ各年龄组均无再通。表明提高溶栓疗效关键是争取时间，认为年龄不应作为限制溶栓的条件，只要时间把握好，无禁忌证，＞７０岁高龄患者仍要积极溶栓，其利大于弊。
To explore the efficacy and security of intravenous thrombolytic therapy in patients of different ages,the urokinase(UK) was intravenously used to 113 patients with acute myocardiac infarction (AMI) onsetting with in 24 hours.The dosage was ranged for 1 to 1.5 million units and it was mixed with 100 ml normal saline in 30 min for intravenous drip.The patients were divided into four groups according to their ages:<49,50～59,60～69 and >70.The results were as follows:①when UK was given within 6 hours after AMI onset,the differences of the repatency rate,complications such as bleeding and death rate within 5 weeks were not significant (P>0.05) among these groups;②when UK was given at 7～12 hours after AMI onset,the repatency rates of the groups under 69 years were near each other (P>0.05);③when UK was given at over 12 hours after AMI onset ,there were no repatency in all treated groups.The facts indicate that the key to improve the efficacy of the thromblytic therapy is time.The earlier,the better.Ages should not be restrictive factor for thrombolytic therapy.
出处
《湖南医学》
1997年第4期197-199,共3页
Hunan Medical Journal
关键词
心肌梗塞
尿激酶
溶栓治疗
年龄
myocardia infarction urokinase thrombolytic therapy
